Allergan plc announced that the U.S. Food and Drug Administration has accepted the New Drug Application (NDA) for ulipristal acetate, an investigational drug for the treatment of abnormal uterine bleeding in women with uterine fibroids. Allergan expects the ulipristal acetate Prescription Drug User Fee Act (PDUFA) action date to occur in the first half of 2018.